| CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL | Cancer Research |  | | 2017 | 550 | 1 |
|
| Revisiting IL-6 antagonism in multiple myeloma | Critical reviews in oncology/hematology |  | | 2016 | 500 | 0 |
|
| Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow | Leukemia |  | | 2015 | 655 | 500 |
|
| Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow | Leukemia |  | | 2015 | 613 | 731 |
|
| Selective APRIL blockade delays systemic lupus erythematosus in mouse | PloS one |  | | 2012 | 627 | 333 |
|
| Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions | Rheumatology |  | | 2011 | 688 | 1 |
|
| Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow | Blood |  | | 2011 | 725 | 1 |
|
| Comment on "Cutting edge: FcR-like 6 is an MHC class II receptor" | The Journal of immunology |  | | 2010 | 592 | 0 |
|
| CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells | European Journal of Immunology |  | | 2010 | 693 | 0 |
|
| Tumors that look for their springtime in APRIL | Critical reviews in oncology/hematology |  | | 2009 | 679 | 0 |
|
| Comment on "Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironment where plasmablasts mature" | The Journal of immunology |  | | 2009 | 552 | 0 |
|
| In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development | Histology and histopathology | | | 2009 | 646 | 0 |
|
| Lymph node tumor metastases: more susceptible than primary tumors to CD8(+) T-cell immune destruction | Trends in immunology |  | | 2009 | 587 | 0 |
|
| Synovial tissues concentrate secreted APRIL | Arthritis research & therapy |  | | 2009 | 678 | 400 |
|
| Heparan sulfate proteoglycans, Fc receptors, and DC suppression | Blood |  | | 2008 | 581 | 0 |
|
| Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas | European journal of cancer |  | | 2008 | 592 | 0 |
|
| Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cells | Cancer research |  | | 2008 | 642 | 0 |
|
| APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells | Blood |  | | 2008 | 684 | 0 |
|
| Reconstitution of the immune system after hematopoietic stem cell transplantation in humans | Seminars in immunopathology |  | | 2008 | 588 | 1,131 |
|
| APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa | The Journal of clinical investigation |  | | 2008 | 684 | 1,020 |
|
| Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases | Experimental hematology |  | | 2008 | 627 | 0 |
|
| Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness | Blood |  | | 2007 | 231 | 302 |
|
| Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes | European Journal of Immunology |  | | 2004 | 277 | 315 |
|